Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/00002030-200207050-00014 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Living Donor Liver Transplantation Using Right Posterior Section Graft in a Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Patient With Hemophilia: A Case Report.
Transplant Proc
January 2025
Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan. Electronic address:
Background: Liver transplantation is an important treatment option for liver cirrhosis in patients with HIV/HCV coinfection. In Japan, the limited number of deceased donors may force the selection of living donor liver transplantation. Appropriate graft selection is the key to success.
View Article and Find Full Text PDFCharacterization of Incident Hepatitis C Virus Infection among People Living with HIV in a HIV Clinic in Korea.
Infect Chemother
December 2024
Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Medical Center, Seoul, Korea.
Background: Coinfection with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) can cause more rapid progression to cirrhosis than HCV-monoinfection. In this study, incident HCV case (IHCV)s were investigated in a HIV clinic in Korea.
Materials And Methods: A retrospective HIV cohort was constructed who visited National Medical Center in Korea from 2013 to 2022 and performed ≥ 1 anti-HCV antibody tests (anti-HCV) during the study period.
Immune checkpoint proteins are associated with persistently high liver stiffness after successful HCV treatment in people with HIV: a retrospective study.
Front Immunol
January 2025
Unidad de Infección Viral e Inmunidad, Centro Nacional de Microbiología (CNM), Instituto de Salud Carlos III (ISCIII), Majadahonda, Madrid, Spain.
Article Synopsis
- This study investigated the link between immune checkpoint proteins and liver stiffness in HIV/HCV-coinfected individuals one year after successful HCV treatment, focusing on plasma levels of these proteins and their correlation with liver stiffness measured five years later.
- 39 patients with advanced liver disease who achieved sustained virologic response (SVR) were analyzed, revealing that although liver stiffness decreased over time, it remained persistently high in 61.5% of participants five years after treatment.
- Elevated levels of immune checkpoints BTLA, PD-1, and TIM-3 were associated with this persistently high liver stiffness, indicating a potential ongoing immunological impact on liver health even after HCV eradication.
Effect of depressive symptoms on health services utilization in the HIV and hepatitis C co-infected population in Canada.
AIDS Care
December 2024
Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec, Canada.
Depression is common among people living with HCV and HIV, which contributes to health services utilization (HSU). It is unknown whether successful HCV treatment affects this. We examined depressive symptoms and HSU in people co-infected with HIV-HCV and their association with sustained virologic response (SVR) during the direct-acting antiviral era.
View Article and Find Full Text PDFEffectiveness of glecaprevir/pibrentasvir in HIV/HCV-coinfected patients treated with bictegravir/emtricitabine/tenofovir alafenamide.
Clin Exp Hepatol
September 2024
Department of Infectious Diseases and Hepatology, Medical University of Białystok, Białystok, Poland.
Aim Of The Study: To assess the real-life efficacy and safety of glecaprevir/pibrentasvir (GLE/PIB) in HIV/HCV- positive patients treated with bictegravir/emtricitabine/tenofovir alafenamide (B/FTC/TAF).
Material And Methods: Patients were evaluated in terms of their baseline biochemical characteristics, which included platelet count, serum creatinine and bilirubin levels, alanine transaminase (ALT) activity, international normalized ratio (INR) and Model for End-Stage Liver Disease (MELD) score.The efficacy endpoint was the achievement of a sustained virologic response at posttreatment week 12 (SVR12), defined as undetectable HCV RNA 12 weeks after the scheduled end of therapy.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!